{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-047941","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.677549+00:00","generated_at":"2026-06-03T08:12:45.643903+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Candel to present CAN-3110 glioma data and CAN-2409 NSCLC topline OS at ASCO 2024","bullets":["Two abstracts accepted for ASCO 2024: CAN-3110 phase 1 (recurrent high-grade glioma, cohort C) and CAN-2409 phase 2 (NSCLC with inadequate ICI response).","CAN-3110 data: multiple injections (up to six) feasible and well tolerated in cohort C.","CAN-2409 presentation will show topline overall survival data with valacyclovir + continued ICI.","Presentations on June 1 (CAN-3110) and June 3 (CAN-2409) at ASCO in Chicago.","Full abstracts released by ASCO on May 23, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-047941","json":"https://secwatch.observer/filing/0000950170-24-047941.json","markdown":"https://secwatch.observer/filing/0000950170-24-047941.md","text":"https://secwatch.observer/filing/0000950170-24-047941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024047941/0000950170-24-047941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024047941/cadl-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:12:45.643903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}